Exemestane Plus Ovarian Suppression Best in Early ILC
New data add to the body of evidence favoring the aromatase inhibitor therapy plus ovarian suppression over tamoxifen for premenopausal women with early invasive lobular carcinoma.
Medscape Medical News
source https://www.medscape.com/viewarticle/exemestane-plus-ovarian-suppression-best-early-invasive-2024a10009tv?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/exemestane-plus-ovarian-suppression-best-early-invasive-2024a10009tv?src=rss
Comments
Post a Comment